Categories: HealthcareNews

Novo Integrated Sciences Reports Fiscal Year 2023 Third Quarter Financial Results

BELLEVUE, Wash.–(BUSINESS WIRE)–$NVOS #AAPI–Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation, today reported its financial results for the third fiscal quarter ended May 31, 2023.


Robert Mattacchione, Novo’s CEO and Board Chairman, stated, “The Company remains committed to the commercialization of its proprietary product offerings and the expansion and delivery of its essential services and solutions of how non-catastrophic healthcare is delivered both now and in the future. During the fiscal year 2023 third quarter period, the Company announced the signing of agreements for an unsecured, non-dilutive 15-year debt instrument, with a principal sum of $70,000,000, which provides for the Company to receive net proceeds of approximately $55,000,000 after fees. In today’s environment of tight capital markets and expensive capital raises, this cash infusion is consequential and will provide the Company with the foundational capital and repayment terms required to support and accelerate the further implementation and growth of Novo’s three-pillar business model. ”

Financial Highlights for the three month period ended May 31, 2023:

  • Cash and cash equivalents were $464,011, total assets were $35.7 million, total liabilities were $9.5 million, and stockholders’ equity was $26.5 million.
  • Revenues were $3,292,933, representing a decrease of $10,558,950, or 76%, from $13,851,883 for the same period in 2022. The decrease in revenue is principally due to the decrease in outsourced product sales and IoNovo Iodine. Acenzia’s and Terragenx’s revenue for the three months ended May 31, 2023 was $896,405 and $5,866, respectively. Revenue from our healthcare services decreased by 8% when comparing the revenue for the three months ended for the same period in 2022.
  • Operating costs were $2,744,512, representing a decrease of $867,116, or 24%, from $3,611,628 for the same period in 2022. The decrease in operating costs was principally due to the decrease in overhead expenses and depreciation and amortization.
  • Net loss attributed to the Company was $1,497,330, representing a decrease of $2,312,724, or 61%, from $3,810,054 for the same period in 2022. The decrease in net loss was principally due to the decrease in operating expenses.
  • On March 21, 2023, the Company issued a $573,000 promissory note (12% per annum interest rate) and completed the related Securities Purchase Agreement with FirstFire Global Opportunities Fund, LLC (“FirstFire”) for gross proceeds of $515,700. The Company granted 5-year warrants with an exercise price of $0.25 per share and issued 955,000 restricted shares to FirstFire.
  • On April 26, 2023, the Company entered into a securities purchase agreement with RC Consulting Group LLC in favor of SCP Tourbillion Monaco or registered assigns pursuant to which the Company issued an unsecured 15-year promissory note to the RC Noteholder (the “RC Note”) with a maturity date of April 26, 2038, in the principal sum of $70,000,000, which amount represents the $57,000,000 purchase price plus a yield (non-compounding) of 1.52% (zero coupon) per annum from April 26, 2023 until the same becomes due and payable as provided in the RC Note.
  • Subsequent to the period ended May 31, 2023, on June 20, 2023, the Company issued a $445,000 promissory note (12% per annum interest rate) and completed the related Securities Purchase Agreement with Mast Hill Fund, L.P. for gross proceeds of $400,500. The Company granted 5-year warrants with an exercise price of $0.25 per share and issued 776,614 restricted shares to Mast Hill Fund, L.P.

About Novo Integrated Sciences, Inc.

Novo Integrated Sciences, Inc. is pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of services and product innovation. Novo offers an essential and differentiated solution to deliver, or intend to deliver, these services and products through the integration of medical technology, advanced therapeutics, and rehabilitative science.

We believe that “decentralizing” healthcare, through the integration of medical technology and interconnectivity, is an essential solution to the rapidly evolving fundamental transformation of how non-catastrophic healthcare is delivered both now and in the future. Specific to non-critical care, ongoing advancements in both medical technology and inter-connectivity are allowing for a shift of the patient/practitioner relationship to the patient’s home and away from on-site visits to primary medical centers with mass-services. This acceleration of “ease-of-access” in the patient/practitioner interaction for non-critical care diagnosis and subsequent treatment minimizes the degradation of non-critical health conditions to critical conditions as well as allowing for more cost-effective healthcare distribution.

The Company’s decentralized healthcare business model is centered on three primary pillars to best support the transformation of non-catastrophic healthcare delivery to patients and consumers:

  • First Pillar: Service Networks. Deliver multidisciplinary primary care services through (i) an affiliate network of clinic facilities, (ii) small and micro footprint sized clinic facilities primarily located within the footprint of box-store commercial enterprises, (iii) clinic facilities operated through a franchise relationship with the Company, and (iv) corporate operated clinic facilities.
  • Second Pillar: Technology. Develop, deploy, and integrate sophisticated interconnected technology, interfacing the patient to the healthcare practitioner thus expanding the reach and availability of the Company’s services, beyond the traditional clinic location, to geographic areas not readily providing advanced, peripheral based healthcare services, including the patient’s home.
  • Third Pillar: Products. Develop and distribute effective, personalized health and wellness product solutions allowing for the customization of patient preventative care remedies and ultimately a healthier population. The Company’s science-first approach to product innovation further emphasizes our mandate to create and provide over-the-counter preventative and maintenance care solutions.

Innovation through science combined with the integration of sophisticated, secure technology assures Novo Integrated Sciences of continued cutting-edge advancement in patient-first platforms.

For more information concerning Novo Integrated Sciences, please visit www.novointegrated.com.

Twitter, LinkedIn, Facebook, Instagram, YouTube

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts included in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by words such as “believe,” “intend,” “expect,” “anticipate,” “plan,” “potential,” “continue” or similar expressions. Such forward-looking statements include risks and uncertainties, and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors, risks and uncertainties are discussed in Novo’s filings with the Securities and Exchange Commission. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond Novo’s control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects Novo’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. Novo assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The contents of any website referenced in this press release are not incorporated by reference herein.

NOVO INTEGRATED SCIENCES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

As of May 31, 2023 (unaudited) and August 31, 2022

 

 

 

May 31,

 

 

August 31,

 

 

 

2023

 

 

2022

 

 

 

(unaudited)

 

 

 

 

ASSETS

 

 

 

 

 

 

 

 

Current Assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

464,011

 

 

$

2,178,687

 

Accounts receivable, net

 

 

1,327,613

 

 

 

1,017,405

 

Inventory, net

 

 

938,940

 

 

 

879,033

 

Other receivables

 

 

1,046,080

 

 

 

1,085,335

 

Prepaid expenses and other current assets

 

 

221,414

 

 

 

571,335

 

Total current assets

 

 

3,998,058

 

 

 

5,731,795

 

 

 

 

 

 

 

 

 

 

Property and equipment, net

 

 

5,411,438

 

 

 

5,800,648

 

Intangible assets, net

 

 

16,696,363

 

 

 

18,840,619

 

Right-of-use assets, net

 

 

2,096,376

 

 

 

2,673,934

 

Goodwill

 

 

7,542,795

 

 

 

7,825,844

 

TOTAL ASSETS

 

$

35,745,030

 

 

$

40,872,840

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current Liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

1,896,040

 

 

$

1,800,268

 

Accrued expenses

 

 

1,178,245

 

 

 

1,116,125

 

Accrued interest (including amounts to related parties)

 

 

350,831

 

 

 

454,189

 

Government loans and notes payable, current portion

 

 

312,672

 

 

 

 

Convertible notes payable, net of discount of $494,523

 

 

651,477

 

 

 

9,099,654

 

Contingent liability

 

 

57,933

 

 

 

534,595

 

Due to related parties

 

 

406,683

 

 

 

478,897

 

Debentures, related parties, current portion

 

 

912,025

 

 

 

 

Finance lease liability, current portion

 

 

13,814

 

 

 

8,890

 

Operating lease liability, current portion

 

 

428,951

 

 

 

582,088

 

Total current liabilities

 

 

6,208,671

 

 

 

14,074,706

 

 

 

 

 

 

 

 

 

 

Debentures, related parties, net of current portion

 

 

 

 

 

946,250

 

Government loans and notes payable, net of current portion

 

 

64,946

 

 

 

161,460

 

Finance lease liability, net of current portion

 

 

 

 

 

12,076

 

Operating lease liability, net of current portion

 

 

1,786,961

 

 

 

2,185,329

 

Deferred tax liability

 

 

1,393,168

 

 

 

1,445,448

 

TOTAL LIABILITIES

 

 

9,453,746

 

 

 

18,825,269

 

 

 

 

 

 

 

 

 

 

Commitments and contingencies

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

Novo Integrated Sciences, Inc.

 

 

 

 

 

 

 

 

Convertible preferred stock; $0.001 par value; 1,000,000 shares authorized; 0 and 0 shares issued and outstanding at May 31, 2023 and August 31, 2022, respectively

 

 

 

 

 

 

Common stock; $0.001 par value; 499,000,000 shares authorized; 144,857,518 and 31,180,603 shares issued and outstanding at May 31, 2023 and August 31, 2022, respectively

 

 

144,857

 

 

 

31,181

 

Additional paid-in capital

 

 

89,249,590

 

 

 

66,056,824

 

Common stock to be issued (911,392 and 4,149,633 shares at May 31, 2023 and August 31, 2022, respectively)

 

 

1,217,293

 

 

 

9,474,807

 

Other comprehensive (loss) income

 

 

(172,526

)

 

 

560,836

 

Accumulated deficit

 

 

(63,872,587

)

 

 

(53,818,489

)

Total Novo Integrated Sciences, Inc. stockholders’ equity

 

 

26,566,627

 

 

 

22,305,159

 

Noncontrolling interest

 

 

(275,343

)

 

 

(257,588

)

Total stockholders’ equity

 

 

26,291,284

 

 

 

22,047,571

 

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

 

$

35,745,030

 

 

$

40,872,840

 

NOVO INTEGRATED SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

For the Three and Nine Months Ended May 31, 2023 and 2022 (unaudited)

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

May 31,

 

 

May 31,

 

 

May 31,

 

 

May 31,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenues

 

$

3,292,933

 

 

$

13,851,883

 

 

$

9,268,722

 

 

$

19,883,033

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenues

 

 

1,978,839

 

 

 

11,443,001

 

 

 

5,244,192

 

 

 

14,991,331

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross profit

 

 

1,314,094

 

 

 

2,408,882

 

 

 

4,024,530

 

 

 

4,891,702

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling expenses

 

 

1,877

 

 

 

9,802

 

 

 

9,916

 

 

 

36,340

 

General and administrative expenses

 

 

2,742,635

 

 

 

3,601,826

 

 

 

9,473,802

 

 

 

9,542,443

 

Total operating expenses

 

 

2,744,512

 

 

 

3,611,628

 

 

 

9,483,718

 

 

 

9,578,783

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss from operations

 

 

(1,430,418

)

 

 

(1,202,746

)

 

 

(5,459,188

)

 

 

(4,687,081

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-operating income (expense)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

62,397

 

 

 

8,355

 

 

 

6,762

 

 

 

25,233

 

Interest expense

 

 

(9,570)

 

 

(513,398

)

 

 

(240,520

)

 

 

(1,808,310

)

Amortization of debt discount

 

 

(156,037

)

 

 

(2,133,890

)

 

 

(4,386,899

)

 

 

(3,654,752

)

Foreign currency transaction gain (loss)

 

 

48,333

 

 

 

97,654

 

 

 

12,652

 

 

 

(303,714

)

Total other expense

 

 

(54,877

)

 

 

(2,541,279

)

 

 

(4,608,005

)

 

 

(5,741,543

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss before income taxes

 

 

(1,485,295

)

 

 

(3,744,025

)

 

 

(10,067,193

)

 

 

(10,428,624

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income tax expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(1,485,295

)

 

$

(3,744,025

)

 

$

(10,067,193

)

 

$

(10,428,624

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss attributed to noncontrolling interest

 

 

12,035

 

 

 

66,029

 

 

 

(13,095

)

 

 

(6,816

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss attributed to Novo Integrated Sciences, Inc.

 

 

(1,497,330

)

 

 

(3,810,054

)

 

 

(10,054,098

)

 

 

(10,421,808

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Comprehensive loss:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

(1,485,295

)

 

 

(3,744,025

)

 

 

(10,067,193

)

 

 

(10,428,624

)

Foreign currency translation (loss) gain

 

 

(120,357

)

 

 

13,711

 

 

 

(738,022

)

 

 

24,916

 

Comprehensive loss:

 

$

(1,605,652

)

 

$

(3,730,314

)

 

$

(10,805,215

)

 

$

(10,403,708

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding – basic and diluted

 

 

143,600,541

 

 

 

29,817,999

 

 

 

85,832,252

 

 

 

28,498,414

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss per common share – basic and diluted

 

$

(0.01

)

 

$

(0.13

)

 

$

(0.12

)

 

$

(0.37

)

NOVO INTEGRATED SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

For the Three and Nine Months Ended May 31, 2023 and 2022 (unaudited)

 

 

 

Common Stock

 

 

Additional

Paid-in

 

 

Common

Stock To

 

 

Other

Comprehensive

 

 

Accumulated

 

 

Novo

Stockholders’

 

 

Noncontrolling

 

 

Total

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Be Issued

 

 

Income

 

 

Deficit

 

 

Equity

 

 

Interest

 

 

Equity

 

Balance, August 31, 2022

 

 

31,180,603

 

 

$

31,181

 

 

$

66,056,824

 

 

$

9,474,807

 

 

$

560,836

 

 

$

(53,818,489

)

 

$

22,305,159

 

 

$

(257,588

)

 

$

22,047,571

 

Units issued for cash, net of offering costs

 

 

4,000,000

 

 

 

4,000

 

 

 

1,791,000

 

 

 

 

 

 

 

 

 

 

 

 

1,795,000

 

 

 

 

 

 

1,795,000

 

Issuance of common stock to be issued

 

 

36,222

 

 

 

36

 

 

 

92,330

 

 

 

(92,366

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cashless exercise of warrants

 

 

4,673,986

 

 

 

4,674

 

 

 

1,134,376

 

 

 

 

 

 

 

 

 

 

 

 

1,139,050

 

 

 

 

 

 

1,139,050

 

Fair value of stock options

 

 

 

 

 

 

 

 

60,887

 

 

 

 

 

 

 

 

 

 

 

 

60,887

 

 

 

 

 

 

60,887

 

Foreign currency translation loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(417,008

)

 

 

 

 

 

(417,008

)

 

 

(3,974

)

 

 

(420,982

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(3,935,413

)

 

 

(3,935,413

)

 

 

(1,323

)

 

 

(3,936,736

)

Balance, November 30, 2022

 

 

39,890,811

 

 

$

39,891

 

 

$

69,135,417

 

 

$

9,382,441

 

 

$

143,828

 

 

$

(57,753,902

)

 

$

20,947,675

 

 

$

(262,885

)

 

$

20,684,790

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Share issuance for convertible debt settlement

 

 

93,109,398

 

 

 

93,110

 

 

 

8,992,941

 

 

 

 

 

 

 

 

 

 

 

 

9,086,051

 

 

 

 

 

 

9,086,051

 

Cashless exercise of warrants

 

 

1,159,348

 

 

 

1,159

 

 

 

281,374

 

 

 

 

 

 

 

 

 

 

 

 

282,533

 

 

 

 

 

 

282,533

 

Exercise of warrants for cash

 

 

1,310,000

 

 

 

1,310

 

 

 

129,690

 

 

 

 

 

 

 

 

 

 

 

 

131,000

 

 

 

 

 

 

131,000

 

Issuance of common stock to be issued

 

 

3,202,019

 

 

 

3,201

 

 

 

8,161,947

 

 

 

(8,165,148

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares issued with convertible notes

 

 

955,000

 

 

 

955

 

 

 

82,008

 

 

 

 

 

 

 

 

 

 

 

 

82,963

 

 

 

 

 

 

82,963

 

Value of warrants issued with convertible notes

 

 

 

 

 

 

 

 

86,327

 

 

 

 

 

 

 

 

 

 

 

 

86,327

 

 

 

 

 

 

86,327

 

Fair value of stock options

 

 

 

 

 

 

 

 

60,887

 

 

 

 

 

 

 

 

 

 

 

 

60,887

 

 

 

 

 

 

60,887

 

Extinguishment of derivative liability due to conversion

 

 

 

 

 

 

 

 

1,390,380

 

 

 

 

 

 

 

 

 

 

 

 

1,390,380

 

 

 

 

 

 

1,390,380

 

Foreign currency translation loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(195,821

)

 

 

 

 

 

(195,821

)

 

 

(862

)

 

 

(196,683

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(4,621,355

)

 

 

(4,621,355

)

 

 

(23,807

)

 

 

(4,645,162

)

Balance, February 28, 2023

 

 

139,626,576

 

 

$

139,626

 

 

$

88,320,971

 

 

$

1,217,293

 

 

$

(51,993

)

 

$

(62,375,257

)

 

$

27,250,640

 

 

$

(287,554

)

 

$

26,963,086

 

Share issuance for convertible debt settlement

 

 

1,075,942

 

 

 

1,076

 

 

 

99,202

 

 

 

 

 

 

 

 

 

 

 

 

100,278

 

 

 

 

 

 

100,278

 

Exercise of warrants for cash

 

 

3,200,000

 

 

 

3,200

 

 

 

316,800

 

 

 

 

 

 

 

 

 

 

 

 

320,000

 

 

 

 

 

 

320,000

 

Shares issued with convertible notes

 

 

955,000

 

 

 

955

 

 

 

89,177

 

 

 

 

 

 

 

 

 

 

 

 

90,132

 

 

 

 

 

 

90,132

 

Value of warrants issued with convertible notes

 

 

 

 

 

 

 

 

93,811

 

 

 

 

 

 

 

 

 

 

 

 

93,811

 

 

 

 

 

 

93,811

 

Beneficial conversion feature upon issuance on convertible debt

 

 

 

 

 

 

 

 

66,068

 

 

 

 

 

 

 

 

 

 

 

 

66,068

 

 

 

 

 

 

66,068

 

Stock option expense

 

 

 

 

 

 

 

 

263,561

 

 

 

 

 

 

 

 

 

 

 

 

263,561

 

 

 

 

 

 

263,561

 

Foreign currency translation loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(120,533

)

 

 

 

 

 

(120,533

)

 

 

176

 

 

 

(120,357

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1,497,330

)

 

 

(1,497,330

)

 

 

12,035

 

 

 

(1,485,295

)

Balance, May 31, 2023

 

 

144,857,518

 

 

$

144,857

 

 

$

89,249,590

 

 

$

1,217,293

 

 

$

(172,526

)

 

$

(63,872,587

)

 

$

26,566,627

 

 

$

(275,343

)

 

$

26,291,284

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, August 31, 2021

 

 

26,610,144

 

 

$

26,610

 

 

$

54,579,396

 

 

$

9,236,607

 

 

$

991,077

 

 

$

(20,969,274

)

 

$

43,864,416

 

 

$

(60,261

)

 

$

43,804,155

 

Common stock for services

 

 

35,000

 

 

 

35

 

 

 

64,715

 

 

 

 

 

 

 

 

 

 

 

 

64,750

 

 

 

 

 

 

64,750

 

Common stock issued as collateral and held in escrow

 

 

2,000,000

 

 

 

2,000

 

 

 

(2,000

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common stock to be issued for purchase of Terragenx

 

 

 

 

 

 

 

 

 

 

 

983,925

 

 

 

 

 

 

 

 

 

983,925

 

 

 

97,311

 

 

 

1,081,236

 

Common stock to be issued for purchase of Mullin assets

 

 

 

 

 

 

 

 

 

 

 

188,925

 

 

 

 

 

 

 

 

 

188,925

 

 

 

 

 

 

188,925

 

Value of warrants issued with convertible notes

 

 

 

 

 

 

 

 

295,824

 

 

 

 

 

 

 

 

 

 

 

 

295,824

 

 

 

 

 

 

295,824

 

Fair value of stock options

 

 

 

 

 

 

 

 

154,135

 

 

 

 

 

 

 

 

 

 

 

 

154,135

 

 

 

 

 

 

154,135

 

Foreign currency translation loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(103,533

)

 

 

 

 

 

(103,533

)

 

 

(855

)

 

 

(104,388

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1,806,587

)

 

 

(1,806,587

)

 

 

(9,808

)

 

 

(1,816,395

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, November 30, 2021

 

 

28,645,144

 

 

$

28,645

 

 

$

55,092,070

 

 

$

10,409,457

 

 

$

887,544

 

 

$

(22,775,861

)

 

$

43,641,855

 

 

$

26,387

 

 

$

43,668,242

 

Common stock for services

 

 

240,000

 

 

 

240

 

 

 

297,760

 

 

 

 

 

 

 

 

 

 

 

 

298,000

 

 

 

 

 

 

298,000

 

Value of warrants issued with convertible notes

 

 

 

 

 

 

 

 

5,257,466

 

 

 

 

 

 

 

 

 

 

 

 

5,257,466

 

 

 

 

 

 

5,257,466

 

Fair value of stock options

 

 

 

 

 

 

 

 

44,427

 

 

 

 

 

 

 

 

 

 

 

 

44,427

 

 

 

 

 

 

44,427

 

Foreign currency translation gain

 

 

 

 

 

 

 

 

 

 

 

 

 

 

114,738

 

 

 

 

 

 

114,738

 

 

 

355

 

 

 

115,093

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(4,805,167

)

 

 

(4,805,167

)

 

 

(63,037

)

 

 

(4,868,204

)

Balance, February 28, 2022

 

 

28,885,144

 

 

$

28,885

 

 

$

60,691,723

 

 

$

10,409,457

 

 

$

1,002,282

 

 

$

(27,581,028

)

 

$

44,551,319

 

 

$

(36,295

)

 

$

44,515,024

 

Common stock issued for services

 

 

125,000

 

 

 

125

 

 

 

313,875

 

 

 

 

 

 

 

 

 

 

 

 

314,000

 

 

 

 

 

 

314,000

 

Share issuance for convertible debt settlement

 

 

623,929

 

 

 

624

 

 

 

1,247,225

 

 

 

 

 

 

 

 

 

 

 

 

1,247,849

 

 

 

 

 

 

1,247,849

 

Common stock issued for acquisition

 

 

800,000

 

 

 

800

 

 

 

1,703,200

 

 

 

 

 

 

 

 

 

 

 

 

1,704,000

 

 

 

 

 

 

1,704,000

 

Common stock to be issued for acquisitions

 

 

 

 

 

 

 

 

 

 

 

260,625

 

 

 

 

 

 

 

 

 

260,625

 

 

 

25,402

 

 

 

286,027

 

Issuance of common stock to be issued

 

 

225,000

 

 

 

225

 

 

 

573,525

 

 

 

(573,750

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fair value of stock options

 

 

 

 

 

 

 

 

91,330

 

 

 

 

 

 

 

 

 

 

 

 

91,330

 

 

 

 

 

 

91,330

 

Foreign currency translation gain

 

 

 

 

 

 

 

 

 

 

 

 

 

 

13,711

 

 

 

 

 

 

13,711

 

 

 

51

 

 

 

13,762

 

Net Loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(3,810,054

)

 

 

(3,810,054

)

 

 

66,029

 

 

 

(3,744,025

)

Balance, May 31, 2022

 

 

30,659,073

 

 

$

30,659

 

 

$

64,620,878

 

 

$

10,096,332

 

 

$

1,015,993

 

 

$

(31,391,082

)

 

$

44,372,780

 

 

$

55,187

 

 

$

44,427,967

 

NOVO INTEGRATED SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

For the Nine Months Ended May 31, 2023 and 2022 (unaudited)

 

 

 

Nine Months Ended

 

 

 

May 31,

 

 

May 31,

 

 

 

2023

 

 

2022

 

 

 

 

 

 

 

 

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

 

 

 

 

 

Net loss

 

$

(10,067,193

)

 

$

(10,428,624

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

1,718,388

 

 

 

2,349,434

 

Fair value of vested stock options

 

 

385,335

 

 

 

289,892

 

Common stock issued for services

 

 

 

 

 

676,750

 

Financing costs for debt extension

 

 

1,421,583

 

 

 

 

Operating lease expense

 

 

624,246

 

 

 

418,188

 

Amortization of debt discount

 

 

4,386,899

 

 

 

3,654,752

 

Foreign currency transaction (gain) loss

 

 

(12,652

)

 

 

303,714

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Accounts receivable

 

 

(308,907

)

 

 

(3,650,069

)

Inventory

 

 

(92,260

)

 

 

(263,539

)

Prepaid expenses and other current assets

 

 

333,724

 

 

 

(150,632

)

Accounts payable

 

 

154,542

 

 

 

117,056

 

Accrued expenses

 

 

104,004

 

 

(68,871

)

Accrued interest

 

 

(67,634)

 

 

 

598,904

 

Operating lease liability

 

 

(594,618

)

 

 

(406,862

)

Net cash used in operating activities

 

 

(2,014,543

)

 

 

(6,559,907

)

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

 

 

 

 

 

Purchase of property and equipment

 

 

(18,870

)

 

 

(190,973

)

Cash acquired with acquisition

 

 

 

 

 

57,489

 

Payments received from other receivables

 

 

 

 

 

296,138

 

Net cash (used in) provided by investing activities

 

 

(18,870

)

 

 

162,654

 

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

 

 

 

 

 

Repayments to related parties

 

 

(56,649)

 

 

 

(21,932

)

Repayments of finance leases

 

 

(6,435

)

 

 

(14,797

)

Proceeds from (repayments of) notes payable

 

 

222,000

 

 

 

(4,430,794

)

Proceeds from the sale of common stock, net of offering costs

 

 

1,795,000

 

 

 

 

Proceeds from exercise of warrants

 

 

451,000

 

 

 

 

Repayment of convertible notes

 

 

(3,033,888

)

 

 

 

Proceeds from issuance of convertible notes, net

 

 

925,306

 

 

 

15,270,000

 

Net cash provided by financing activities

 

 

296,334

 

 

 

10,802,477

 

 

 

 

 

 

 

 

 

 

Effect of exchange rate changes on cash and cash equivalents

 

 

22,403

 

 

 

(20,940

)

 

 

 

 

 

 

 

 

 

NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS

 

 

(1,714,676

)

 

 

4,384,284

 

 

 

 

 

 

 

 

 

 

CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD

 

 

2,178,687

 

 

 

8,293,162

 

 

 

 

 

 

 

 

 

 

CASH AND CASH EQUIVALENTS, END OF PERIOD

 

$

464,011

 

 

$

12,677,446

 

 

 

 

 

 

 

 

 

 

CASH PAID FOR:

 

 

 

 

 

 

 

 

Interest

 

$

343,878

 

 

$

1,294,912

 

Income taxes

 

$

 

 

$

 

 

 

 

 

 

 

 

 

 

SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES:

 

 

 

 

 

 

 

 

Common stock issued for convertible debt settlement

 

$

9,186,329

 

 

$

1,247,849

 

Common stock to be issued for intangible assets

 

$

 

 

$

188,925

 

Common stock to be issued for acquisition

 

$

 

 

$

1,244,550

 

Common stock issued for acquisition

 

$

 

 

$

1,704,000

 

Beneficial conversion feature upon issuance of convertible notes

 

$

66,068

 

 

$

 

Debt discount recognized on derivative liability

 

$

1,390,380

 

 

$

 

Debt discount recognized on convertible note

 

$

639,993

 

 

$

 

Extinguishment of derivative liability due to conversion

 

$

1,390,380

 

 

$

 

Common stock issued with convertible notes

 

$

173,095

 

 

$

 

Warrants issued with convertible notes

 

$

180,138

 

 

$

 

Contacts

Chris David, COO-President

Novo Integrated Sciences, Inc.

chris.david@novointegrated.com
(888) 512-1195

Read full story here

Staff

Recent Posts

Sona’s Cancer Therapy Triggers Abscopal Effect, Eliminating Distant Tumors In Preclinical Melanoma Study

Halifax, Nova Scotia--(Newsfile Corp. - June 26, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB:…

24 mins ago

Bemax Inc. Announces UK Distribution Hub for Reduced Lead Time on Orders

Dallas, Georgia--(Newsfile Corp. - June 26, 2024) - Bemax Inc. (OTC Pink: BMXC), a private…

1 hour ago

Lifeward Unveils Newest Addition to Its AlterG Anti-Gravity Product Line – Introducing AlterG NEO

Elevate your practice and revolutionize patient care with the all-new user-friendly design and the same…

1 hour ago

BioStem Technologies Reports Breakthrough Results with AmnioWrap2® in Retrospective Wound Care Study

Study published in peer-reviewed journal finds BioStem’s products offer overall better treatment efficiency, and greater…

1 hour ago

Aclarion Announces Initial Payer Coverage of Nociscan by AXA Throughout Greater London, UK

AXA is the 2nd Largest Provider of Private Medical Insurance in the UK Payer Coverage…

1 hour ago

University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx’s Pivotal Phase III TIGeR-PaC Clinical Trial

Ongoing Study is Investigating RenovoGem™ to treat Locally Advanced Pancreatic CancerLOS ALTOS, Calif., June 26, 2024…

1 hour ago